Cargando…

Generation of interleukin-13 receptor alpha2 antigen expressing modified vaccinia ankara recombinant virus for potential cancer immunotherapy

Detalles Bibliográficos
Autores principales:	Sato, Yuki, Vatsan, Ramjay, Joshi, Bharat H, Husain, Syed R, Puri, Raj K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288700/ http://dx.doi.org/10.1186/2051-1426-2-S3-P58

Ejemplares similares

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
por: Czub, Markus, et al.
Publicado: (2005)

Interleukin 13 receptor alpha 2 directed immunotherapy targets hepatic fibrosis and tumorigenesis induced by choline deficient diet in an in vivo mouse model of nonalcoholic steatohepatitis
por: Fujisawa, Toshio, et al.
Publicado: (2014)

Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice
por: Bohnen, C, et al.
Publicado: (2013)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
por: Pathan, Ansar A., et al.
Publicado: (2007)

Regenerative Medicine Therapies for Rare Diseases
por: Lapteva, Larissa, et al.
Publicado: (2018)

Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
por: Vatsan, Ramjay S, et al.
Publicado: (2013)

Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen
por: Knudsen, Maria L., et al.
Publicado: (2015)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
por: Pathan, Ansar A., et al.
Publicado: (2011)

Interleukin-1β receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1β activity produced in various virus-infected antigen-presenting cells
por: Zimmerling, Stefan, et al.
Publicado: (2013)

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
por: Altenburg, Arwen F., et al.
Publicado: (2017)

Analysis of interleukin-13 receptor alpha2 expression as a prognostic biomarker in surgically resected pancreatic cancer patients
por: Fujisawa, Toshio, et al.
Publicado: (2015)

Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
por: Cottingham, Matthew G., et al.
Publicado: (2008)

Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage
por: Lehmann, Michael H, et al.
Publicado: (2015)

Purification of modified vaccinia virus Ankara from suspension cell culture
por: Jordan, Ingo, et al.
Publicado: (2015)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Jordan, Ingo, et al.
Publicado: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Orlova, Olga Vladimirovna, et al.
Publicado: (2022)

Modified vaccinia Ankara–Bavarian Nordic vaccine against mpox in children
por: Turtle, Lance, et al.
Publicado: (2023)

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
por: Drexler, Ingo, et al.
Publicado: (2004)

Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy
por: Knudson, Karin M., et al.
Publicado: (2022)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
por: Cottingham, Matthew G., et al.
Publicado: (2011)

The production of recombinant platelet‐derived growth factor D using the second generation modified vaccinia Ankara viral system
por: Najy, Abdo J., et al.
Publicado: (2022)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert, P, et al.
Publicado: (2012)

Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine
por: Lopera-Madrid, Jaime, et al.
Publicado: (2017)

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
por: Préville, Xavier, et al.
Publicado: (2015)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
por: Okeke, Malachy I., et al.
Publicado: (2017)

A vital gene for modified vaccinia virus Ankara replication in human cells
por: Sutter, Gerd
Publicado: (2020)

Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara
por: Jordan, Ingo, et al.
Publicado: (2009)

Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)
por: Chiam, Rachael, et al.
Publicado: (2009)

OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs
por: Yang, Ning, et al.
Publicado: (2023)

Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease
por: Joshi, Bharat H, et al.
Publicado: (2014)

Immune Requirements of Post-Exposure Immunization with Modified Vaccinia Ankara of Lethally Infected Mice
por: Lauterbach, Henning, et al.
Publicado: (2010)

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes
por: Lülf, Anna-Theresa, et al.
Publicado: (2016)

Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy
por: Hebben, Matthias, et al.
Publicado: (2004)

Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion
por: Song, Guang-Yun, et al.
Publicado: (2011)

Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate
por: Currier, Jeffrey R., et al.
Publicado: (2010)

Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccines Efficiently Protect Cockatiels Against Parrot Bornavirus Infection and Proventricular Dilatation Disease
por: Rall, Isabell, et al.
Publicado: (2019)

Interleukin-4 receptor targeted immunotherapy of human bladder cancer in animal models
por: Joshi, Bharat H, et al.
Publicado: (2014)

Modified Vaccinia Virus Ankara Can Induce Optimal CD8(+) T Cell Responses to Directly Primed Antigens Depending on Vaccine Design
por: Wong, Yik Chun, et al.
Publicado: (2019)

Recombinant Modified Vaccinia Virus Ankara Expressing Glycoprotein E2 of Chikungunya Virus Protects AG129 Mice against Lethal Challenge
por: van den Doel, Petra, et al.
Publicado: (2014)

Expanding the Repertoire of Modified Vaccinia Ankara-Based Vaccine Vectors via Genetic Complementation Strategies
por: Garber, David A., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_jdcsolsukvl1iv7jfh31162rg6